Home
INDV
INDV News

Latest Indivior PLC (INDV) News on September 6, 2025

Indivior to Participate in Upcoming Investor Events

PR Newswire

16 days ago

Indivior to Participate in Upcoming Investor Events

Indivior Appoints Tony Kingsley to the Board of Directors

PR Newswire

2 months ago

Indivior Appoints Tony Kingsley to the Board of Directors

Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com

3 months ago

Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and ...

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

PR Newswire

3 months ago

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Wise Plans to Shift Main Listing to US in Latest London Loss

Bloomberg

3 months ago

Wise Plans to Shift Main Listing to US in Latest London Loss

The Telegraph

3 months ago

FTSE pharma giant joins London stock market exodus

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

PR Newswire

3 months ago

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Indivior Announces Patrick Barry as Chief Commercial Officer

PR Newswire

3 months ago

Indivior Announces Patrick Barry as Chief Commercial Officer

Investors in Indivior (LON:INDV) have seen solid returns of 156% over the past five years

Simply Wall St.

3 months ago

Investors in Indivior (LON:INDV) have seen solid returns of 156% over the past five years

Indivior to Participate in Upcoming Investor Events

PR Newswire

4 months ago

Indivior to Participate in Upcoming Investor Events

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

PR Newswire

4 months ago

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

Indivior First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

4 months ago

Indivior First Quarter 2025 Earnings: Beats Expectations

Indivior PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Simply Wall St.

4 months ago

Indivior PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates

Zacks

4 months ago

Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates

Indivior Announces Q1 2025 Financial Results

PR Newswire

4 months ago

Indivior Announces Q1 2025 Financial Results

Is Indivior PLC (INDV) the Best Stock to Buy According to Howard Marks’ Oaktree Capital Management?

Insider Monkey

5 months ago

Is Indivior PLC (INDV) the Best Stock to Buy According to Howard Marks’ Oaktree Capital Management?

Indivior Insiders Placed Bullish Bets Worth US$1.42m

Simply Wall St.

6 months ago

Indivior Insiders Placed Bullish Bets Worth US$1.42m

Indivior Announces Further Changes to Board of Directors

PR Newswire

6 months ago

Indivior Announces Further Changes to Board of Directors

Is Indivior PLC (INDV) the Best Small Cap Pharma Stock to Buy Now?

Insider Monkey

6 months ago

Is Indivior PLC (INDV) the Best Small Cap Pharma Stock to Buy Now?

MT Newswires

6 months ago

Indivior Names Joe Ciaffoni as Chief Executive

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

PR Newswire

6 months ago

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

PR Newswire

6 months ago

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Indivior Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

6 months ago

Indivior Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Indivior PLC (INDV) (Q4 2024) Earnings Call Highlights: Strong SUBLOCADE Growth and Strategic ...

GuruFocus.com

7 months ago

Indivior PLC (INDV) (Q4 2024) Earnings Call Highlights: Strong SUBLOCADE Growth and Strategic ...

MT Newswires

7 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires

7 months ago

Sector Update: Health Care

MT Newswires

7 months ago

Top Midday Decliners

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Benzinga

7 months ago

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Earnings To Watch: Indivior PLC (INDV) Reports Q4 2024 Result

GuruFocus.com

7 months ago

Earnings To Watch: Indivior PLC (INDV) Reports Q4 2024 Result

Indivior PLC (INDV) Q4 Earnings Meet Estimates

Zacks

7 months ago

Indivior PLC (INDV) Q4 Earnings Meet Estimates

MT Newswires

7 months ago

Indivior's Q4 Adjusted Earnings Fall, Revenue Rises

Indivior Announces FY and Q4 2024 Financial Results

PR Newswire

7 months ago

Indivior Announces FY and Q4 2024 Financial Results

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Zacks

7 months ago

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

MT Newswires

7 months ago

Indivior Says US FDA Delays on Sublocade Label Changes Decision

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

PR Newswire

7 months ago

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

Here’s Summers Value Partners’ Investment Thesis for Indivior (INDV)

Insider Monkey

7 months ago

Here’s Summers Value Partners’ Investment Thesis for Indivior (INDV)

Great week for Indivior PLC (LON:INDV) institutional investors after losing 23% over the previous year

Simply Wall St.

8 months ago

Great week for Indivior PLC (LON:INDV) institutional investors after losing 23% over the previous year

Indivior (LON:INDV) shareholder returns have been enviable, earning 366% in 5 years

Simply Wall St.

9 months ago

Indivior (LON:INDV) shareholder returns have been enviable, earning 366% in 5 years

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...

GuruFocus.com

9 months ago

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

PR Newswire

10 months ago

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

PR Newswire

10 months ago

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

PR Newswire

10 months ago

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ...

GuruFocus.com

10 months ago

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ...

Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates

Zacks

10 months ago

Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates

Indivior Announces Q3 2024 Financial Results

PR Newswire

10 months ago

Indivior Announces Q3 2024 Financial Results

Indivior PLC (INDV) Q3 2024 Earnings Report Preview: What to Expect

GuruFocus.com

10 months ago

Indivior PLC (INDV) Q3 2024 Earnings Report Preview: What to Expect

Two Seas Capital LP Increases Stake in Indivior PLC

GuruFocus.com

a year ago

Two Seas Capital LP Increases Stake in Indivior PLC

Indivior price target lowered to $16 from $20 at Craig-Hallum

TipRanks

a year ago

Indivior price target lowered to $16 from $20 at Craig-Hallum

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ...

GuruFocus.com

a year ago

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ...

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details

Benzinga

a year ago

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details

MT Newswires

a year ago

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

PR Newswire

a year ago

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

MT Newswires

a year ago

Indivior Gets FDA Priority Review on Prior Approval Supplement for Sublocade

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

PR Newswire

a year ago

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...

GuruFocus.com

a year ago

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...

Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?

Zacks

a year ago

Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?

Top 3 Health Care Stocks That May Explode This Month

Benzinga

a year ago

Top 3 Health Care Stocks That May Explode This Month

Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder

PR Newswire

a year ago

Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder

Addex Stock Soars on Crucial Update From Indivior Research Deal

Zacks

a year ago

Addex Stock Soars on Crucial Update From Indivior Research Deal

Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder

Benzinga

a year ago

Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder

MT Newswires

a year ago

Indivior Says BARDA Makes 1st Order of Opioid Overdose Reversal Nasal Spray

Indivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness

PR Newswire

a year ago

Indivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness

MT Newswires

a year ago

Indivior to Pay $86 Million in Multistate Opioid Settlement, New York Attorney General Says

Indivior reaches $86 million opioid settlement with 16 US states

Reuters

a year ago

Indivior reaches $86 million opioid settlement with 16 US states

MT Newswires

a year ago

Indivior Shares Rise After Q2 Adjusted Earnings, Revenue Rise

Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates

Zacks

a year ago

Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates

Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame

PR Newswire

a year ago

Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame

Indivior Announces Q2 2024 Financial Results

PR Newswire

a year ago

Indivior Announces Q2 2024 Financial Results

Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for

Zacks

a year ago

Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Zacks

a year ago

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

Zacks

a year ago

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

Top Premarket Decliners

MT Newswires

a year ago

Indivior Lowers Fiscal 2024 Net Revenue Guidance, to Discontinue Antipsychotic Injection Perseris -- Shares Tumble Premarket

Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT

PR Newswire

a year ago

Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT

Pulling back 10% this week, Indivior's LON:INDV) five-year decline in earnings may be coming into investors focus

Simply Wall St.

a year ago

Pulling back 10% this week, Indivior's LON:INDV) five-year decline in earnings may be coming into investors focus

Indivior CEO Expects Ongoing U.S. Opioid Crisis to Drive Sales Growth

The Wall Street Journal

a year ago

Indivior CEO Expects Ongoing U.S. Opioid Crisis to Drive Sales Growth

Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest

PR Newswire

a year ago

Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest

Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder

PR Newswire

a year ago

Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder

With 59% ownership, Indivior PLC (LON:INDV) boasts of strong institutional backing

Simply Wall St.

a year ago

With 59% ownership, Indivior PLC (LON:INDV) boasts of strong institutional backing

Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance

PR Newswire

a year ago

Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance

GuruFocus.com

a year ago

Indivior PLC (INDV) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ...

Why Indivior PLC (LON:INDV) Looks Like A Quality Company

Simply Wall St.

a year ago

Why Indivior PLC (LON:INDV) Looks Like A Quality Company

Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates

Zacks

a year ago

Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates

Reuters

a year ago

UPDATE 1-UK-listed drugmaker Indivior seeks shareholder nod for US listing

Reuters

a year ago

Drugmaker Indivior to seek shareholder nod on shifting primary listing to US

Indivior Confirms Plan to Switch Listing From London to New York

Bloomberg

a year ago

Indivior Confirms Plan to Switch Listing From London to New York

Indivior Announces Q1 2024 Financial Results

PR Newswire

a year ago

Indivior Announces Q1 2024 Financial Results

Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?

Zacks

a year ago

Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?

Indivior PLC (INDV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks

a year ago

Indivior PLC (INDV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

PR Newswire

a year ago

Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia

Zacks

a year ago

Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia

Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata

Zacks

a year ago

Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata

Zacks.com featured highlights Modine Manufacturing, Indivior and Interface

Zacks

a year ago

Zacks.com featured highlights Modine Manufacturing, Indivior and Interface

Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat

Zacks

2 years ago

Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

Zacks

2 years ago

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat

Zacks

2 years ago

Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

PR Newswire

2 years ago

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

Earnings Update: Indivior PLC (LON:INDV) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Simply Wall St.

2 years ago

Earnings Update: Indivior PLC (LON:INDV) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Health Care Roundup: Market Talk

The Wall Street Journal

2 years ago

Health Care Roundup: Market Talk

Share on Social Networks: